Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Videos

Chemotherapy De-escalation for HER2-Positive Early Breast Cancer

3-Year Invasive Disease-Free Survival Results From the PHERGain Trial


Javier Cortes, MD, PhD, International Breast Cancer Center, Madrid, Spain, discusses results from the PHERGain study, evaluating chemotherapy de-escalation strategies in HER2-positive early breast cancer, presented at the 2023 ASCO Annual Meeting.

 


Source:

Cortes J, Pérez-García JM, Ruiz Borrego M, et al. 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC). Presented at 2023 ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract LBA506

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of INSERT BRAND or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement